17,261 trials
Atrial Fibrillation (AF)
Primary: Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding — 3…
Metastatic Renal Cell Carcinoma · Advanced Urothelial Carcinoma · Advanced Gastric Adenocarcinoma
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6 — 0; 1; 0; 0 Participants
Neovascular Age-related Macular Degeneration
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Per the Early Treatment Diabetic Retinopathy Study (ETDRS) Testing Method — 10.4; 6.7; 13.7 score on a…
Breast Neoplasms
Primary: Pathologic Complete Response (pCR) — 25 Participants
Polycystic Ovary Syndrome
Primary: Mean Percent Body Weight Loss — -7.67 percentage of weight — p=<.001
HIV-1 Infections
Primary: The Percentage of Women With the Composite Endpoint of Abnormal Safety Findings. — 23; 28; 28 Participants
Solid Tumors
Primary: The Number of Participants Experiencing Drug-Related Grade 3-4 Adverse Events (AEs) — 1; 1; 0; 0 Participants
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Gastroenteritis Norovirus
Primary: Time to Initial Clinical Resolution of Norovirus Symptoms — 19; 11 days — p=0.459
Pruritus · Atopic Dermatitis
Primary: Reduction of Itching in AD — 1.70; 1.55 score on a scale
Human Immunodeficiency Virus
Primary: The Safety of Dapivirine (25 mg) Administered Via a Silicone Vaginal Ring in HIV-uninfected Adolescent Females, When Inserted Once Every 4 Weeks During 24 Weeks of Study…
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Oral Squamous Cell Carcinoma
Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants